The following is a listing of myeloma treatments associated with this tag.
View all treatments in development for myeloma patients around the US.
ABBV-383
ABBV-383 is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with multiple myeloma who have received one to two prior lines of therapy.
ABBV-383
ABBV-383 is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with multiple myeloma who have received three or more prior lines of therapy.
ABBV-383
ABBV-383 is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of myeloma clinical trials associated with this tag.
View all active clinical trials around the US.
SparkCures Verified Accurate, up-to-date information. Learn more
A Phase 1b/2 Study of Talquetamab Plus Concomitant Priming Radiotherapy in Multiple Myeloma With Extramedul...
RADIATION + TALQUETAMAB FOR EXTRAMEDULLARY DISEASEA Phase 2 Study of Elranatamab as Consolidation After Idecabtagene Vicleucel in Relapsed Refractory Multipl...
ELRANATAMAB AS CONSOLIDATIONA Phase Ib, Multi-center, Study of Talquetamab in Combination With Iberdomide and Dexamethasone for the Tre...
TALQUETAMAB WITH IBERDOMIDEA Randomized, Placebo-controlled, Parallel-group, Investigator- and Participant-blinded Phase 2a Study to I...
CHIP PATIENTS WITH CORONARY HEART DISEASEMeasurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
MRD-GUIDED ELRANATAMAB MAINTENANCE THERAPYMMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
HORIZON ADAPTIVE PLATFORMPhase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy for Relapsed/Refractory Multipl...
CEVOSTAMAB AFTER CAR-T CELL THERAPYPre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With...
PRE AND POST TRANSPLANT ELRANATAMABProvide Compassionate Use' of REGN5458 for Patients with Relapsed or Refractory Multiple Myeloma
LINVOSELTAMAB - COMPASSIONATE USETalquetamab Consolidation After BCMA CART Cell Therapy for Relapsed or Refractory Multiple Myeloma
TALQUETAMAB CONSOLIDATION AFTER BCMA CAR-TThe following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.
SparkCures Verified Accurate, up-to-date information. Learn more
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
MRD-GUIDED ELRANATAMAB MAINTENANCE THERAPYPre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With...
PRE AND POST TRANSPLANT ELRANATAMABThe following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
SparkCures Verified Accurate, up-to-date information. Learn more
A Phase 1b/2 Study of Talquetamab Plus Concomitant Priming Radiotherapy in Multiple Myeloma With Extramedul...
RADIATION + TALQUETAMAB FOR EXTRAMEDULLARY DISEASEA Phase Ib, Multi-center, Study of Talquetamab in Combination With Iberdomide and Dexamethasone for the Tre...
TALQUETAMAB WITH IBERDOMIDETalquetamab Consolidation After BCMA CART Cell Therapy for Relapsed or Refractory Multiple Myeloma
TALQUETAMAB CONSOLIDATION AFTER BCMA CAR-TThe following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
SparkCures Verified Accurate, up-to-date information. Learn more
A Phase 1b/2 Study of Talquetamab Plus Concomitant Priming Radiotherapy in Multiple Myeloma With Extramedul...
RADIATION + TALQUETAMAB FOR EXTRAMEDULLARY DISEASEA Phase 2 Study of Elranatamab as Consolidation After Idecabtagene Vicleucel in Relapsed Refractory Multipl...
ELRANATAMAB AS CONSOLIDATIONA Phase Ib, Multi-center, Study of Talquetamab in Combination With Iberdomide and Dexamethasone for the Tre...
TALQUETAMAB WITH IBERDOMIDEPhase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy for Relapsed/Refractory Multipl...
CEVOSTAMAB AFTER CAR-T CELL THERAPYTalquetamab Consolidation After BCMA CART Cell Therapy for Relapsed or Refractory Multiple Myeloma
TALQUETAMAB CONSOLIDATION AFTER BCMA CAR-TThe following is a listing of clinical trials for patients with Smoldering Myeloma.
The following is a listing of clinical trials for patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).
The following is a listing of myeloma tags that are associated with this tag.
B-Cell Maturation Antigen (BCMA)
B-Cell Maturation Antigen (BCMA) is a protein that may be found on the surface of myeloma cells. BCMA may be used as a target to help treatments find and destroy myeloma cells.
GPRC5D
GPRC5D is a protein that may be found on the surface of myeloma cells. This protein may be used as a way for treatments to target (or find) myeloma cells.